Camrelizumab Vs Placebo With Chemotherapy As Neoadjuvant Treatment In Triple-Negative Breast Cancer JAMA Author Interviews podcast

Artwork

Science Fitness Medicine American Medical Association JAMA Network Research Interviews Journalism Authors

内容由American Medical Association and JAMA Network提供。所有播客内容（包括剧集、图形和播客描述）均由 American Medical Association and JAMA Network 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。

JAMA Author Interviews « »
Camrelizumab vs Placebo With Chemotherapy as Neoadjuvant Treatment in Triple-Negative Breast Cancer

2M ago 15:14

分享

MP3•单集首页

内容由American Medical Association and JAMA Network提供。所有播客内容（包括剧集、图形和播客描述）均由 American Medical Association and JAMA Network 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。

Triple-negative breast cancer accounts for around 15% of breast cancers. Zhi-Ming Shao, MD, of Fudon University, joins JAMA Oncology Editor in Chief and JAMA Deputy Editor Nora Disis, MD, to discuss "Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients with Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial." Related Content:

Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer

… continue reading

844集单集

#Science #Fitness #Medicine #American Medical Association #JAMA Network #Research #Interviews #Journalism #Authors

Artwork

Camrelizumab vs Placebo With Chemotherapy as Neoadjuvant Treatment in Triple-Negative Breast Cancer

JAMA Author Interviews

published 2M ago

分享

MP3•单集首页

内容由American Medical Association and JAMA Network提供。所有播客内容（包括剧集、图形和播客描述）均由 American Medical Association and JAMA Network 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。

Triple-negative breast cancer accounts for around 15% of breast cancers. Zhi-Ming Shao, MD, of Fudon University, joins JAMA Oncology Editor in Chief and JAMA Deputy Editor Nora Disis, MD, to discuss "Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients with Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial." Related Content:

Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer

… continue reading

844集单集

#Science #Fitness #Medicine #American Medical Association #JAMA Network #Research #Interviews #Journalism #Authors

所有剧集

×

欢迎使用Player FM

Player FM正在网上搜索高质量的播客，以便您现在享受。它是最好的播客应用程序，适用于安卓、iPhone和网络。注册以跨设备同步订阅。

收听超过500个主题

边探索边听这个节目